Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLVA combination therapy for advanced EBV-positive nasopharyngeal carcinoma
NL-OMON22299Phase 2Recruiting
- Sponsor
- sponsor:ZonMW perfomers: the Netherlands Cancer Institute/ Antoni van Leeuwenhoek Hospital
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, valproic acid and valganciclovir in nasopharyngeal carcinoma (NPC), sponsored by sponsor:ZonMW perfomers: the Netherlands Cancer Institute/ Antoni van Leeuwenhoek Hospital. Primary endpoint: Safety and tolerability. Started Feb 2011; status: recruiting.
02
Drugs
gemcitabinevalproic acidvalganciclovir
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NL-OMON22299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22299.